CRISPR Therapeutics Price Target, Predictions & Analyst Ratings

+1.48 (+1.15 %)
(As of 06/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume960,733 shs
Average Volume1.83 million shs
Market Capitalization$9.90 billion
P/E RatioN/A
Dividend YieldN/A

CRISPR Therapeutics (NASDAQ:CRSP) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for CRISPR Therapeutics in the last 12 months. Their average twelve-month price target is $157.67, predicting that the stock has a possible upside of 20.65%. The high price target for CRSP is $210.00 and the low price target for CRSP is $110.00. There are currently 1 sell rating, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
TypeToday30 Days Ago90 Days Ago180 Days Ago
CRSP Consensus Rating: BuyBuyBuyBuy
CRSP Consensus Rating Score: 2.652.632.562.56
CRSP Analyst Ratings: 1 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
3 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
CRSP Consensus Price Target: $157.67$160.88$158.80$136.54
CRSP Price Target Upside: 20.65% upside21.05% upside18.95% upside9.85% upside

CRISPR Therapeutics (NASDAQ:CRSP) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CRISPR Therapeutics (NASDAQ:CRSP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell
UpgradeSell ➝ Neutral$55.00 ➝ $132.00Low
5/13/2021Evercore ISI
Boost Price TargetOverweight$140.00 ➝ $160.00High
4/21/2021Jefferies Financial Group
UpgradeHold ➝ Buy$172.00Medium
3/4/2021JMP Securities
Initiated CoverageOutperform$160.00High
2/17/2021The Goldman Sachs Group
Lower Price TargetNeutral$193.00 ➝ $189.00Medium
Boost Price TargetOutperform$165.00 ➝ $187.00Low
2/17/2021Chardan Capital
Boost Price TargetBuy$166.00 ➝ $175.00Low
2/17/2021Needham & Company LLC
Reiterated RatingBuyLow
Boost Price Target$170.00 ➝ $210.00Low
12/10/2020Piper Sandler
Boost Price TargetOverweight$107.00 ➝ $180.00Medium
12/7/2020Stifel Nicolaus
Boost Price TargetHold ➝ Positive$91.00 ➝ $145.00High
12/7/2020Canaccord Genuity
Boost Price TargetBuy$120.00 ➝ $151.00Low
12/7/2020Roth Capital
Boost Price TargetBuy$115.00 ➝ $170.00High
12/7/2020Wells Fargo & Company
DowngradeOverweight ➝ Equal Weight$102.63 ➝ $145.00Low
10/30/2020Raymond James
Reiterated RatingSellHigh
10/22/2020Royal Bank of Canada
Initiated CoverageSector Perform$110.00 ➝ $110.00Medium
10/5/2020Bank of America
Initiated CoverageBuy$110.00 ➝ $110.00High
7/28/2020William Blair
Reiterated RatingBuyMedium
7/14/2020SunTrust Banks
Initiated CoverageBuy$140.00Low
12/16/2019Piper Jaffray Companies
Reiterated RatingBuy$104.00Low
7/30/2019BTIG Research
Boost Price TargetBuy ➝ Positive$51.00 ➝ $59.00Medium
Initiated CoverageNeutral ➝ NeutralLow
(Data available from 6/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.